Castle Biosciences (CSTL) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Castle Biosciences (CSTL) has outperformed Myriad Genetics (MYGN) over the past year, gaining 42.9% versus a loss of 45.0%. Over five years, CSTL leads with a -47.0% price change compared with -86.8% for MYGN. Castle Biosciences is the larger company by market cap ($1.03 billion vs $401.7 million), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSTL | MYGN |
|---|---|---|
| Share price | $33.71 | $4.20 |
| Market cap | $1.03B | $401.73M |
| 1-day change | +2.15% | -1.87% |
| YTD return | -13.34% | -31.71% |
| 1-year return | +42.90% | -45.03% |
| 5-year return | -46.98% | -86.77% |
| EPS (TTM) | $-0.64 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.28 | $8.59 |
| 52-week low | $17.72 | $2.74 |
| Distance from 52-week high | -23.87% | -51.11% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +33.82% | -6.90% |
| Average volume | 402.90K | 2.02M |
| Shares outstanding | 30.55M | 95.65M |
| Employees | 1,002 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Castle Biosciences is about 2.6 times larger than Myriad Genetics by market value ($1.03B vs $401.73M).
- CSTL has outperformed MYGN by 87.9 percentage points over the past year.
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,002 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
CSTL vs MYGN FAQ
Which is bigger, Castle Biosciences or Myriad Genetics?
Castle Biosciences (CSTL) is larger, with a market capitalization of $1.03B compared with $401.73M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, CSTL or MYGN?
CSTL returned +42.90% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Castle Biosciences and Myriad Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Castle Biosciences and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Myriad Genetics.